Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
BERWYN, Pa., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases, was issued a patent (US 10,383,851) in August 2019 for a method of treating P...
BERWYN, Pa., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases, announced today that the Data Safety Monitoring Board has reviewed the safety...
BERWYN, Pa., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE American: ANVS), a clinical stage, drug platform company addressing Alzheimer's, Parkinson's and other neurodegenerative diseases, today announced the closing of its initial public offering of 2,000,000 shares of its com...
Annovis Bio ( ANVS ) has priced its initial public offering of 2M common shares at $6.00 per share, for gross proceeds of $12M. More news on: Annovis Bio, Healthcare stocks news, IPO News, Read more ...
BERWYN, Pa., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Annovis Bio, Inc., a clinical stage, drug platform company addressing Alzheimer's, Parkinson's and other neurodegenerative diseases today announced the pricing of its initial public offering of 2,000,000 shares of its common stock at a price to...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Quick Take Annovis Bio ( OTC:ANVS ) intends to raise $10 million in an IPO of its common stock, per an amended registration statement . The company is developing a pipeline of treatment candidates for the treatment of various neurodegenerative conditions. ANVS is working on some of the ...
Quick Take Annovis Bio ( OTC:ANVS ) has filed to raise gross proceeds of up to $11.5 million from a U.S. IPO, according to an S-1 registration statement . The firm is focused on developing therapeutics for chronic and acute neurodegeneration disorders. ANVS is a tiny firm seeking to sol...
There we no IPOs during the shortened holiday week. However, we expect a number of new launches in the coming week . This past week, eight IPOs joined the IPO pipeline, including four aiming to raise $100 million or more, as well as one SPAC. Thoma Bravo's software management platform Dynat...
News, Short Squeeze, Breakout and More Instantly...
Annovis announced in June 2024 that they had filed a composition of matter patent for their new crystal form of buntanetap, along with a provisional patent for the manufacturing process The company’s goal is to use this technology to restore brain function and improve the quality of life...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...